The estimated Net Worth of Erin Burkhart is at least 1.49 百万$ dollars as of 13 August 2024. Erin Burkhart owns over 714 units of Biomarin Pharmaceutical stock worth over 1,224,986$ and over the last 3 years Erin sold BMRN stock worth over 270,000$.
Erin has made over 2 trades of the Biomarin Pharmaceutical stock since 2024, according to the Form 4 filled with the SEC. Most recently Erin sold 714 units of BMRN stock worth 64,260$ on 13 August 2024.
The largest trade Erin's ever made was selling 2,286 units of Biomarin Pharmaceutical stock on 10 April 2024 worth over 205,740$. On average, Erin trades about 429 units every 18 days since 2022. As of 13 August 2024 Erin still owns at least 14,449 units of Biomarin Pharmaceutical stock.
You can see the complete history of Erin Burkhart stock trades at the bottom of the page.
Erin's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREEET, SAN RAFAEL, CA, 94901.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over 153,109,113$ worth of Biomarin Pharmaceutical stock and bought 151,118 units worth 2,557,509$ . The most active insiders traders include Jean Jacques Bienaime、Mark J Enyedy、Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of 912,996$. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth 64,260$.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: